Original news and analysis on international IP policy
The newly created Medicines Patent Pool promises to increase access to HIV/AIDS medications in developing markets. Based in Geneva, Switzerland, the pool operates a scheme in which pharmaceutical patent holders voluntarily licence their drugs to generic manufacturers who then produce more affordable versions for patients in poorer countries
After three days of intense negotiations on the role of the World Health Organization in the fight against low standard or falsified medicines, delegates provided recommendations for the UN agency. A subject of dissent was the relationship between the WHO and its taskforce against counterfeit medicines, with some countries calling for a suspension of the taskforce’s work, though in the end no consensus was found.
The role of the World Health Organization in the safety, quality and efficacy of medical products is under scrutiny this week by member states and stakeholders. In particular, the focus is on the WHO’s role in the prevention and control of medical products of compromised quality, the organisation’s relationship with the international taskforce against counterfeit products, and the taskforce’s alleged focus on the protection of intellectual property rights rather than on public health issues. In several documents, the WHO tries to explain this fragile role.
A designated working group will meet for the first time this week to discuss the World Health Organization’s role in the safety, quality and efficacy of medical products, but some countries are concerned about what they consider to be the unwelcome intrusion of intellectual property rights issues into the debate.
On the eve of a meeting of the WHO working group on substandard/spurious/falsely-labelled/falsified/counterfeit medical products, research-based pharmaceutical industry group IFPMA sets out thoughts on building global consensus to address fake medicines.
Patents and public health are sometimes seen as a mismatch, but three prominent international organisations today stepped up their collaboration on ways to facilitate access to medicines by making a better use of the patent system. Effective, reliable and transparent information on patents is necessary to help decision-makers take the best public health approaches for global health coverage, panellists said.
The Executive Board session of the World Health Organization ended early on Monday after a week of discussions that settled some issues but left some others for the next governing meeting of the organisation in May, with much to do until then. The WHO is facing a significant gap in its budget and a programme of reforms is brewing.
World Health Organization members yesterday struck a compromise allowing a Swiss industry representative to sit on a committee selecting proposals for research and developing financing for neglected diseases, disregarding the fact that he is author of one of the proposals. Special safeguards were added to prevent undue influence, but questions remain for some about a conflict of interest.
World Health Organization members today raised strong concerns that a working group they mandated last May to address problems with WHO policy on counterfeit and substandard medicines has yet to be formed - with four months remaining before it must report back to members.
One delegation called for a halt to WHO activities on anti-counterfeiting until the outcome of the working group is accepted by member states.
With the World Health Organization director general’s term of office ending next year, WHO members today set up a drafting group to try to reconcile divergent views on the process leading to the election. Some countries are in favour of a principle of geographical rotation - citing over 60 years of no representation from their regions, while some other countries claimed rotation could override more important selection criteria such as expertise and experience, and could endanger the organisation’s future.
A seemingly overworked and impoverished World Health Organization opened its Executive Board session today with calls for reform amid deep concerns about its financial future. Meanwhile, dissension arose over an industry representative named by the WHO secretariat to a new research and development funding working group, sparking the WHO director general to cast doubt on the role of industry in such groups.
A top Swiss company executive on pandemic influenza and HIV/AIDS research took the reins of the Geneva-based Medicines for Malaria Venture this week, just weeks after MMV was given international organisation status by the Swiss government.